test sustanon

In the first week test sustanon administered at a dose of 3 million IU per week, the second week – 9 MIU 3 times a week, and then – 18 million IU 3 times a week (in case of intolerance to the dose can be reduced to 9 MIU 3 times a week). During this period, vinblastine administered intravenously according to the instructions for use of the drug at a dose of 0.1 mg / kg of 1 every 3 weeks.

Duration of treatment: . At least 3 months, maximum – up to 12 months. or until disease progression. If complete remission treatment can be discontinued 3 months. after its occurrence.

9 million IU 3 times a week up to 12 months. or until disease progression. Treatment can be started at a dose of 3 or 6 MIU and gradually increase to 9 million IU (the recommended dose) for the first 2 weeks (in case of intolerance to the dose can be reduced to 3 million IU 3 times a week).

Roferon ® -A administered after infusion of the drug Avastin (on the same day or 2-3 days) (see. Also on the use of Avastin instructions).

Metastatic melanoma
18 million IU three times per week or at the maximum tolerated dose for at least 12 weeks. The duration of treatment to evaluate the effectiveness of therapy – preferably – not less than 12 weeks. If you have a treatment effect is continued in his absence – stop. The maximum duration of treatment was 24 months.

Melanoma after surgical resection
adjuvant therapy with low doses of the drug test sustanon increases the length of time without disease recurrence in patients without lymph node involvement and distant metastases following resection of a melanoma (tumor thickness> 1.5 mm). The treatment should be initiated no later than 6 weeks after surgery. Dose: 3 MIU 3 times a week. Duration of treatment – 18 months.

Chronic active hepatitis B
usually 4.5-9 million IU administered three times per week for 4-6 months. Further dose adjustment is carried out, depending on tolerability. If after 3-4 months. no improvement is observed, it is necessary to consider the termination of therapy.

Chronic hepatitis C
Efficacy of interferon alpha-2a is enhanced if it is administered in combination with ribavirin.  May be appointed as monotherapy in case of intolerance and / or contraindication to ribavirin.

Combination therapy with test sustanon and ribavirin previously untreated patients with chronic hepatitis C: 3 million IU 3 times a week for 6 months. Dosage of Ribavirin: see above and on the medical use of ribavirin instructions..

Combination therapy and ribavirin for recurrent chronic hepatitis C: by 4.5 million IU 3 times a week for 6 months. The standard duration of therapy for patients with chronic hepatitis C depends on the source characteristics of the patient (eg, genotype) and is 6-12 months.

Dosage of Ribavirin: see relevant instructions for medical use of ribavirin..

3-6 million IU three times per week for 6-12 months.

If after 3 months. treatment ALT levels not normalized, therapy should be discontinued.

If portability and partial or complete response to therapy , but the relapse of the disease after its cancellation, possible effect of re-therapy test sustanon in the same or a higher dose.

Genital warts
1-3 million IU three times per week for 1-2 months.

Precautions
Should be administered under the supervision of a physician who is experienced in the treatment of the relevant indications.

Proper treatment of the underlying disease and complications is possible only when adequate diagnostic and therapeutic opportunities.

In mild and moderate renal impairment, liver or bone marrow of their functional state must be carefully controlled.

Changes in hepatic function. Caution should be exercised in the treatment of interferon-alpha in patients with chronic hepatitis with autoimmune diseases in history. Every patient who in the treatment  there are pathological changes in the functional liver samples, it is necessary to closely monitor and stop the drug if necessary. In the treatment of interferon alpha rarely observed severe liver and liver failure.

Neuropsychiatric changes. In patients receiving interferons, including may manifest severe psychiatric adverse reactions. Depression, suicidal ideation and suicide may occur in patients with a history of mental illness, and without it. Caution should be exercised when therapy  in patients with a history of depression. We recommend close monitoring of patients receiving test sustanon the purpose of identification of depression. Prior to treatment patients should be informed about the possibility of depression, and patients should be immediately reported to your doctor about any symptoms of depression; in the case of depression should consult a psychiatrist and the question of the appropriateness of treatment discontinuation.